Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Co Enzyme Q10 Together With Fertility Drugs on Pregnancy Outcome of in Vitro Fertilization

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 35-43 years at the time of enrollment~* Diagnosis of primary infertility~Exclusion Criteria:~* Body mass index (BMI) \> 38 kg/m2~* Early follicular phase (day 2-4) serum FSH level \> 20 mIU/ml.~* Abnormal uterine cavity as evidenced by sonohysterogram or hysterosalpingography~* Any current use of systemic steroid medication or any infertility treatment within 3 months of study enrollment.~* Any contraindication to being pregnant and carrying a pregnancy to term.~* Contraindication for the use of CoQ10, Superfact, Puregon, hCG, Estrace and Progesterone suppositories.~* Any ovarian or abdominal abnormality that may interfere with adequate TVS evaluation.~* Absence of one or two ovaries~* Clinically relevant systemic disease (e.g., Insulin-dependent diabetes, adrenal dysfunction, organic intracranial lesion, polycystic ovarian syndrome, hyperprolactinemia, or hypothalamic tumor) or serious illness (Neoplasia).~* History (within past 12 months) or current abuse of alcohol or drugs.~* Administration of any investigational drugs within three months prior to study enrollment.~* Any medical condition that may interfere with the absorption, distribution, metabolism or excretion of the study drugs, gastrointestinal diseases, mal absorption syndromes and liver dysfunction~* Unexplained gynecological bleeding.~* Ejaculated sperm is not sufficient for ICSI~* Patient not able to communicate adequately with the investigators and to comply with the requirements of the entire study.~* Abnormal COH screening blood done for both partners, including: prolactin, thyroid stimulating hormone, HIV serology, Hepatitis B and C serology, Rubella, group and screen and syphilis serology prior to participation in study.~* Unwillingness to give written informed consent. Previous entry into this study or simultaneous participation in another clinical trial.~* The concurrent use of any of the following drugs:~* Daunorubicin, Doxorubicin, Blood Pressure Medications, Warfarin, Timolol, atorvastatin, cerivastatin, lovastatin, pravastatin, simvastatin gemfibrozil, tricyclic antidepressant medications (including amitriptyline, amoxapine, clomipramine, desipramine, doxepin, imipramine, nortriptyline, protriptyline, and trimipramine) multivitamins or any vitamin supplementation except Folic acid.

- Gender: FEMALE
- Minimum Age: 35 Years
- Maximum Age: 43 Years
- Healthy Volunteers: t

Study Arms:
- CoQ10 (Type: EXPERIMENTAL): This group will be treated concomitantly with Coenzyme Q10
- Control (Type: PLACEBO_COMPARATOR): Treated with capsules containing the vehicle.

Based on this trial design, predict the completion outcome and termination type (if applicable).